Cyclodextrins in nasal drug delivery

Advanced Drug Delivery Reviews

Volumn 36, Issue 1, 1999, Pages 41-57

  Merkus, F W H M ^a   Verhoef, J C ^a   Marttin, E ^a   Romeijn, S G ^a   Van Der Kuy, P H M ^a   Hermens, W A J J ^a   Schipper, N G M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Cyclodextrin toxicity; Insulin; Interspecies differences; Methylated cyclodextrins; Nasal drug absorption; Nasal mucociliary clearance

Indexed keywords

DERIVATIVES; DRUG INFUSION; DRUG PRODUCTS; TOXICITY;

CYCLODEXTRINS; NASAL DRUG DELIVERY;

POLYSACCHARIDES;

2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; BUSERELIN; CALCITONIN; CORTICOTROPIN DERIVATIVE; CYCLODEXTRIN DERIVATIVE; DIHYDROERGOTAMINE; ESTRADIOL; GLUCAGON; INSULIN LISPRO; LEUPRORELIN; MELATONIN; MORPHINE; OLIGOPEPTIDE; PIRODAVIR; PROGESTERONE; PROTEIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

CILIARY MOTILITY; CYTOTOXICITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SAFETY; HEMOLYSIS; HUMAN; IN VITRO STUDY; INTRANASAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; REVIEW; SPECIES DIFFERENCE;

EID: 0033104268     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(98)00054-4     Document Type: Review

References (81)

1. W.A.J.J. Hermens, M.J.M. Deurloo, S.G. Romeijn, J.C. Verhoef, F.W.H.M. Merkus, Nasal absorption enhancement of 17-β-oestradiol by dimethyl-β-cyclodextrin in rabbits and rats, Pharm. Res. 7 (1990) 500-503.
2. N.G.M. Schipper, W.A.J.J. Hermens, S.G. Romeijn, J. Verhoef, F.W.H.M. Merkus, Nasal absorption of 17-β-estradiol and progesterone from a dimethyl-β-cyclodextrin inclusion formulation in rats, Int. J. Pharm. 64 (1990) 61-66.
3. W.A.J.J. Hermens, C.W.J. Belder, J.M.W.M. Merkus, P.M. Hooymans, J. Verhoef, F.W.H.M. Merkus, Intranasal estradiol administration to oophorectomized women, Eur. J. Obstet. Gynecol. Reprod. Biol. 40 (1991) 35-41.
4. W.A.J.J. Hermens, C.W.J. Beider, J.M.W.M. Merkus, P.M. Hooymans, J. Verhoef, F.W.H.M. Merkus, Intranasal administration of estradiol in combination with progesterone to oophorectomized women: a pilot study, Eur. J. Obstet. Gynecol. Reprod. Biol. 43 (1992) 65-70.
5. F.G. Hayden, K. Andries, P.A.J. Jansen, Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection, Antimicrob. Agents Chemother. 36 (1992) 727-732.
6. T. Kondo, K. Nishimura, M. Hirata, T. Irie, K. Uekama, Effects of cyclodextrins on nasal absorption and analgesic activity of opioids in rats, in: J. Szejtli, L. Szente (Eds.), Proceedings of the Eighth International Symposium on Cyclodextrins, Kluwer Academic Publishers, Dordrecht, 1996, pp. 387-390.
7. F.W.H.M. Merkus, T.J. Janssen, P.J.M. Guelen, Phamacokinetics of intranasal morphine in healthy subjects, Thérapie 50 (5) (1995) Abstract 402.
8. E. Marttin, S.G. Romeijn, J.C. Verhoef, F.W.H.M. Merkus, Nasal absorption of dihydroergotamine from liquid and powder formulations in rabbits, J. Pharm. Sci. 86 (1997) 802-807.
9. P.H.M. van der Kuy, J.J.H.M. Lohman, P.M. Hooymans, J.W.M. Ter Berg, F.W.H.M. Merkus, Pharmacokinetics of intranasal formulations of dihydroergotamine, abstract in Br, J. Clin. Pharmacol. 46 (1998) 623.
10. F.W.H.M Merkus, Nasal melatonin compositions, International Patent application PCT/EP 98/01783, (1998) 1-21.
11. N.G.M. Schipper, J.C. Verhoef, L.M. De Lannoy, S.G. Romeijn, J.H. Brakkee, V.M. Wiegant, W.H. Gispen, F.W.H.M. Merkus, Nasal administration of an ACTH(4-9) peptide analog with dimethyl-β-cyclodextrin as an absorption enhancer: pharmacokinetics and dynamics, Br. J. Pharmacol. 110 (1993) 1335-1340.
12. K. Matsubara, K. Abe, T. Irie, K. Uekama, Improvement of nasal bioavailability of luteinizing hormone-releasing hormone agonist, buserelin, by cyclodextrin derivatives in rats, J. Pharm. Sci. 84 (1995) 1295-1300.
13. A. Adjei, D. Sundberg, J. Miller, A. Chun, Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans, Pharm. Res. 9 (1992) 244-249.
14. N.G.M. Schipper, J.C. Verhoef, S.G. Romeijn, F.W.H.M. Merkus, Methylated β-cyclodextrins are able to improve the nasal absorption of salmon calcitonin, Calcif. Tissue Int. 56 (1995) 280-282.
15. F.M. Sakr, Nasal administration of glucagon combined with dimethyl-β-cyclodextrin: comparison of pharmacokinetics and pharmacodynamics of spray and powder formulations, Int. J. Pharm. 132 (1996) 189-194.
16. F.W.H.M. Merkus, J. Verhoef, S.G. Romeijn, N.G.M. Schipper, Absorption enhancing effect of cyclodextrins on intranasally administered insulin in rats, Pharm. Res. 8 (1991) 588-592.
17. N.G.M. Schipper, J. Verhoef, S.G. Romeijn, F.W.H.M. Merkus, Absorption enhancers in nasal insulin delivery and their influence on nasal ciliary functioning, J. Control. Release 21 (1992) 173-186.
18. T. Irie, K. Wakamatsu, H. Arima, H. Aritomi, K. Uekama, Enhancing effects of cyclodextrins on nasal absorption of insulin in rats, Int. J. Pharm. 84 (1992) 129-139.
19. N.G.M. Schipper, S.G. Romeijn, J.C. Verhoef, F.W.H.M. Merkus, Nasal insulin delivery with dimethyl-β-cyclodextrin as an absorption enhancer in rabbits: powder more effective than liquid formulations, Pharm. Res. 10 (1993) 682-686.
20. Y. Watanabe, Y. Matsumoto, K. Kawamoto, S. Yazawa, M. Matsumoto, Enhancing effects of cyclodextrins on nasal absorption of insulin and its duration in rabbits, Chem. Pharm. Bull. 40 (1992) 3100-3104.
21. F.W.H.M. Merkus, N.G.M. Schipper, J.C. Verhoef, The influence of absorption enhancers on the intranasal insulin absorption in normal and diabetic subjects, J. Control. Release 41 (1996) 69-75.
22. A.E. Pontiroli, A. Calderara, G. Pozza, Intranasal drug delivery; potential advantages and limitations from a clinical pharmacokinetic perspective, Clin. Pharmacokinet. 17 (1989) 299-307.
23. L. Ilium, S. Davis, Intranasal insulin: clinical pharmacokinetics, Clin. Pharmacokinet. 23 (1992) 30-41.
24. A.C. Moses, G.S. Gordon, M.C. Carey, J.S. Fier, Insulin administered intranasally as an insulin-bile salt aerosol, Diabetes 32 (1983) 1040-1047.
25. A.E. Pontiroli, M. Alberetto, E. Pajetta, A. Calderara, G. Pozza, Human insulin plus sodium glycocholate in a nasal spray formulation: improved bioavailability and effectiveness in normal subjects, Diabetes Metab. 13 (1987) 441-443.
26. M.S. Nolte, C. Taboga, E. Salamon, A. Moses, J. Longenecker, J. Flier, J.H. Karam, Biological activity of nasally administered insulin in normal subjects, Horm. Metab. Res. 22 (1990) 170-174.
27. K. Drejer, A. Vaag, K. Bech, P. Hansen, A.R. Sorensen, N. Mygind, Intranasal administration of insulin with phospholipid as absorption enhancer: pharmacokinetics in normal subjects, Diabetes Med. 9 (1992) 335-340.
28. M.A. Jacobs, R.H. Schreuder, K. Jap-A-Joe, J.J. Nauta, P.M. Andersen, R.J. Heine, The pharmacodynamics and activity of intranasally administered insulin in healthy male volunteers, Diabetes 42 (1993) 1649-1655.
29. J. Hilsted, S. Madsbad, A. Hvidberg, M.H. Rasmussen, T. Krarup, H. Ipsen, B. Hansen, M. Pedersen, R. Djurup, B. Oxenboll, Intranasal insulin therapy: the clinical realities, Diabetologica 38 (1995) 680-684.
30. Y. Watanabe, Y. Matsumoto, M. Yamaguchi, R. Kikuchi, K. Takayama, H. Nomura, K. Maruyama, M. Matsumoto, Absorption of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and blood leukocyte dynamics following intranasal administration in rabbits, Biol. Pharm. Bull. 16 (1993) 93-95.
31. Y. Watanabe, Y. Matsumoto, R. Kikuchi, M. Kiriyama, R. Ito, M. Matsumoto, H. Nomura, K. Maruyama, Absorption and blood leukocyte dynamics of recombinant human granulecyte colony-stimulating factor (rhG-CSF) from intranasally administered preparations containing rhG-CSF and cyclodextrins in rabbits, Int. J. Pharm. 110 (1994) 93-97.
32. F.W.H.M. Merkus, J. Verhoef, S.G. Romeijn, N.G.M. Schipper, Interspecies differences in the nasal absorption of insulin, Pharm. Res. 8 (1991) 1343.
33. W.A. Lee, B.A. Narog, T.W. Patapoff, Y.J. Wang, Intranasal bioavailability of insulin powder formulations: effect of permeation enhancer to protein ratio, J. Pharm. Sci. 80 (1991) 725-729.
34. J.F. Landa, J.A. Hirsch, M.I. Lebeaux, Effects of topical and general anesthetics on tracheal mucous velocity in sheep, J. Appl. Physiol. 38 (1975) 946-948.
35. A.R. Forbes, G. Gamsu, Mucociliary clearance in canine lung during and after general anesthesia, Anesthesiology 50 (1979) 26-29.
36. L. Ilium, Nasal delivery. The use of animal models to predict performance in man, J. Drug Target. 3 (1996) 427-442.
37. E. Marttin, J.C. Verhoef, S.G. Romeijn, P. Zwart, F.W.H.M. Merkus, Acute histopathological effects of benzalkonium chloride and absorption enhancers on rat nasal epithelium in vivo, Int. J. Pharm. 141 (1996) 151-160.
38. I. Jabbal Gill, A.N. Fisher, M. Hinchcliffe, J. Whetstone, N. Farraj, R. De Ponti, L. Illum, Cyclodextrins as protection agents against enhancer damage in nasal delivery systems. II. Effect on in vivo absorption of insulin and histopathology of nasal membrane, Eur. J. Pharm. Sci. 1 (1994) 237-248.
39. E. Marttin, J.C. Verhoef, C. Cullander, S.G. Romeijn, J.F. Nagelkerke, F.W.H.M. Merkus, Confocal laser scanning microscopic visualization of the transport of dextrans after nasal administration to rats: effects of absorption enhancers, Pharm. Res. 14 (1997) 631-637.
40. E. Marttin, N.G.M. Schipper, J.C. Verhoef, F.W.H.M. Merkus, Nasal mucociliary clearance as a factor in nasal drug delivery, Adv. Drug Del. Rev. 29 (1998) 13-38.
41. H.J.M. Van de Donk, J. Zuidema, F.W.H.M. Merkus, Correlation between the sensitivity of the ciliary beat frequency of human adenoid tissue and chicken embryo tracheas for some drugs, Rhinology 20 (1982) 81-87.
42. W.A.J.J. Hermens, P.M. Hooymans, J.C. Verhoef, F.W.H.M. Merkus, Effects of absorption enhancers on human nasal tissue ciliary movement in vitro, Pharm. Res. 7 (1990) 144-146.
43. S.G. Romeijn, J.C. Verhoef, E. Marttin, F.W.H.M. Merkus, The effect of nasal drug formulations on ciliary beating in vitro, Int. J. Pharm. 135 (1996) 137-145.
44. F.W.H.M. Merkus, N.G.M. Schipper, W.A.J.J. Hermens, S.G. Romeijn, J.C. Verhoef, Absorption enhancers in nasal drug delivery: efficacy and safety, J. Control. Release 24 (1993) 201-208.
45. E. Marttin, J.C. Verhoef, S.G. Romeijn, F.W.H.M. Merkus, Effects of absorption enhancers on rat nasal epithelium in vivo: release of marker compounds in the nasal cavity, Pharm. Res. 12 (1995) 1151-1157.
46. Z. Shao, R. Krishnamoorthy, A.K. Mitra, Cyclodextrins as nasal absorption promoters of insulin-mechanistic evaluations, Pharm. Res. 9 (1992) 1157-1163.
47. R. Krishnamoorthy, A.M. Wolka, Z. Shao, A.K. Mitra, Cyclodextrins as mucosal absorption promoters IV. Evaluation of nasal mucotoxicity, Eur. J. Pharm. Biopharm. 41 (1995) 296-301.
48. F.W.H.M. Merkus, E. Marttin, S.G. Romeijn, J. Verhoef, In situ perfusion is an unrealistic approach to assess the effects of absorption enhancers on nasal epithelium, Eur. J. Pharm. Biopharm. 42 (1996) 159.
49. S. Gizurarson, The relevance of nasal physiology to the design of drug absorption studies, Adv. Drug Del. Rev. 11 (1993) 329-347.
50. G. Silber, D. Proud, J. Warner, R. Naclerio, A. Kagey-Sobotka, L. Lichtenstein, P. Eggleston, In vivo release of inflammatory mediators by hyperosmolar solutions, Rev. Respir. Dis. 137 (1988) 606-612.
51. T.C. Sim, A. Grant, K.A. Hilsmeier, Y. Fukuda, R. Alam, Proinflammatory cytokines in nasal secretions of allergic subjects after antigen challenge, Am. J. Respir. Crit. Care Med. 149 (1994) 339-344.
52. J.M. Stadel, K. Hoyle, R.M. Naclerio, A. Roshak, F.H. Chilton, Characterization of phospholipase A2 from human nasal lavage, Am. J. Respir. Cell Mol. Biol. 11 (1994) 408-413.
53. T. Nitta, T. Hoshino, M. Koida, H. Nakmuta, Histomorphometrical evaluation of anti-osteopenic effect of nasal salmon calcitonin in type 1 osteoporotic model of rats, Biol. Pharm. Bull. 19 (1996) 214-216.
54. K. Uekama, M. Otagiri, Cyclodextrins in drug carrier systems, Crit. Rev. Ther. Drug Carrier Syst. 3 (1987) 1-40.
55. H. Nakamuta, T. Nitta, T. Hoshino, M. Koida, Glucocorticoid-induced osteopenia in rats: histomorphometrical and microarchitectural characterization and calcitonin effect, Biol. Pharm. Bull. 19 (1996) 217-219.
56. Y. Ohtani, T. Irie, K. Uekama, K. Fukunaga, J. Pitha, Differential effects of α-, β-, and γ-cyclodextrin on human erythrocytes, Eur. J. Biochem. 186 (1989) 17-22.
57. I. Jodál, P. Nánási, J. Szejtli, Investigation in the hemolytic effect of the cyclodextrin derivatives, in: O. Huber, J. Szejtli (Eds.), Proceedings of the Fourth International Symposium on Cyclodextrins, Kluwer Academic Publishers, Dordrecht, 1988, pp. 407-413.
58. A. Yoshida, H. Arima, K. Uekama, J. Pitha, Pharmaceutical evaluation of hydroxyalkyl ethers of β-cyclodextrins, Int. J. Pharm. 46 (1988) 217-222.
59. M. Yamamoto, A. Yoshida, F. Hirayama, K. Uekama, Some physicochemical properties of branched β-cyclodextrins and their inclusion characteristics, Int. J. Pharm. 46 (1989) 217-222.
60. F. Leroy-Lechat, M. Skiba, D. Wouessidjewe, D. Duchêne, Cytotoxicity of cyclodextrins and derivatives, in: A.R. Hedges (Ed.), Minutes of the 6th International Symposium on Cyclodextrins, Editions de Santé, Paris, 1992, pp. 292-297.
61. R.P. Garay, J.C. Feray, C. Nazaret, K. Fanous, M.J. Villegas, J.F. Letavernier, A new approach for the in vitro evaluation of cyclodextrin effects on cellular membranes of human cells, in: T. Osa (Ed.), Proceedings 7th International Cyclodextrin Symposium, Komiyama Printing Co., Tokyo, 1994, pp. 373-376.
62. J. Pitha, Pharmacological role of hydroxypropyl cyclodextrins, in: D. Duchêne (Ed.), New Trends in Cyclodextrins and Derivatives, Editons de Santé, Paris, 1991, p. 353.
63. P.G. Yancey, W.V. Rodrigueza, E.P.C. Kilsdonk, G.W. Stoudt, W.J. Johnson, M.C. Phillips, G.H. Rothblat, Cellular cholesterol efflux mediated by cyclodextrins. Demonstration of kinetic pools and mechanism of efflux, J. Biol. Chem. 271 (1996) 16026-16034.
64. F. Leroy-Lechat, D. Wouessidjewe, J.-P. Andreux, F. Puisieux, D. Duchêne, Evaluation of the cytotoxicity of cyclodextrins and hydroxypropylated derivatives, Int. J. Pharm. 101 (1994) 97-103.
65. E.P.C. Kilsdonk, P.G. Yancey, G.W. Stoudt, F.W. Bangerter, W.J. Johnson, M.C. Phillips, G.H. Rothblat, Cellular cholesterol efflux mediated by cyclodextrins, J. Biol. Chem. 270 (1995) 17250-17256.
66. L. Hovgaard, H. Bronsted, Drug delivery studies in Caco-2 monolayers. IV. Absorption enhancer effects of cyclodextrins, Pharm. Res. 12 (1995) 1328-1332.
67. A.M. Tötterman, N.G.M. Schipper, D.O. Thompson, J.P. Mannermaa, Intestinal safety of water-soluble β-cyclodextrins in paediatric solutions of spironolactone: effects on human intestinal epithelial Caco-2 cells, J. Pharm. Pharmacol. 49 (1997) 43-48.
68. D. Duchêne, D. Wouessidjewe, Physicochemical characteristics and pharmaceutical uses of cyclodextrin derivatives, Pharm. Technol. Int. June (1990) 21-29.
69. D. Duchêne, D. Wouessidjewe, Pharmaceutical uses of cyclodextrins and derivatives, Drug Dev. Ind. Pharm. 16 (1990) 2487-2499.
70. J. Szejtli, Dimethyl-β-cyclodextrin as parenteral drug carrier, J. Incl. Phen. 1 (1983) 135-150.
71. E. Albers, B.W. Müller, Cyclodextrin derivatives in pharmaceutics, Crit. Rev. Ther. Drug Carrier Syst. 12 (1995) 311-337.
72. D.O. Thompson, Cyclodextrins - enabling excipients: their present and future use in pharmaceuticals, Crit. Rev. Ther. Drug Carrier Syst. 14 (1997) 1-104.
73. R.A. Rajewski, V.J. Stella, Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery, J. Pharm. Sci. 85 (1996) 1142-1169.
74. H.J.E.M. Reeuwijk, H. Irth, U.R. Tjaden, F.W.H.M. Merkus, J. Van der Greef, Liquid chromatographic determination of β-cyclodextrin derivatives based on fluorescence enhancement after inclusion complexation, J. Chromatogr. 614 (1993) 95-101.
75. P. Szabo, T. Ferenczy, J. Serfözö, A. Liptáp, Absorption and elimination of cyclodextrin derivatives by rabbits and rats, in: J. Szejtli (Ed.), Proceedings of the 1st International Symposium on Cyclodextrins, Kluwer Academic Publishers, Dordrecht, 1982, p. 115.
76. I. Szatmári, Z. Vargay, Pharmacokinetics of dimethyl-β-cyclodextrin in rats, in: O. Huber, J. Szejtli (Eds.), Proceedings of the Fourth International Symposium on Cyclodextrins, Kluwer Academic Publishers, Dordrecht, 1988, pp. 407-413.
77. P. Olivier, F. Verwaerde, A.R. Hedges, Subchronic toxicity of orally administered beta-cyclodextrin in rats, J. Am. Coll. Toxicol. 10 (1991) 407-419.
78. J.H. Perrin, F.P. Field, D.A. Hansen, R.A. Mufson, G. Torosian, β-cyclodextrin as an aid to peritoneal dialysis. Renal toxicity of β-cyclodextrin in the rat, Res. Commun. Chem. Pathol. Pharmacol. 19 (1978) 373.
79. D. Frank, J.E. Gray, R.N. Weaver, Cyclodextrin nephrosis in the rat, Am. J. Pathol. 83 (1976) 367.
80. H.W. Frijlink, A.C. Eissens, N.R. Hefting, K. Poelstra, C.F. Lerk, D.K.F. Meijer, The effect of parenterally administered cyclodextrins on cholesterol levels in the rat, Pharm. Res. 8 (1991) 9-16.
81. G. Antlsperger, G. Schmid, Toxicological comparison of cyclodextrins, in: J. Szejtli, L. Szente (Eds.), Proceedings of the Eighth International Symposium on Cyclodextrins, Kluwer Academic Publishers, Dordrecht, 1996, pp. 149-155.